ABT-494 (Upadacitinib)

upadacitinib · AbbVie

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABT-494 (Upadacitinib), covering 2020-07-16 to 2020-07-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis [Phase 2]